Ark Therapeutics Group PLC said it has received a 2.19 mln eur grant from the Employment and Economic Development Centre of Finland for its new GMP manufacturing facility. The facility is currently being prepared for commercial-scale manufacture of Cerepro, a gene-based medicine for the treatment of brain cancer. The new facility will significantly increase Ark's manufacturing capacity and scope in the gene-based medicines. Work on the facility has already commenced and Ark Therapeutics expects it to be operational for validation to commence towards the end of 2007.
Interactive Investor (http://www.iii.co.uk/news/?type=afxnews&articleid=5454190&subject=economic&action=article)